Saw palmetto extract: newest (and oldest) treatment alternative for men with symptomatic benign prostatic hyperplasia (Q95796553)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10096366%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

editorial

0 references

title

Saw palmetto extract: newest (and oldest) treatment alternative for men with symptomatic benign prostatic hyperplasia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10096366%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

main subject

prostatic hypertrophy

1 reference

L S Marks

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10096366%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

V E Tyler

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10096366%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

publication date

1 March 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10096366%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10096366%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

volume

53

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10096366%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10096366%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

page(s)

457-461

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10096366%20AND%20SRC:MED&resulttype=core&format=json

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

30 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900567-6

7 January 2021

Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900567-6

7 January 2021

Maximum efficacy of finasteride is obtained within 6 months and maintained over 6 years. Follow-up of the Scandinavian Open-Extension Study. The Scandinavian Finasteride Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900567-6

7 January 2021

Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900567-6

7 January 2021

Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900567-6

7 January 2021

Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. Finasteride PSA Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900567-6

7 January 2021

The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900567-6

7 January 2021

Transition zone volume and transition zone ratio: predictor of uroflow response to finasteride therapy in benign prostatic hyperplasia patients

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900567-6

7 January 2021

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900567-6

7 January 2021

TREATMENT OF BENIGN PROSTATIC HYPERTROPHY WITH HYDROXYPROGESTERONE CAPROATE: EFFECT ON CLINICAL SYMPTOMS, MORPHOLOGY, AND ENDOCRINE FUNCTION.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900567-6

7 January 2021

Medical treatment of benign nodular prostatic hyperplasia with cyproterone acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900567-6

7 January 2021

The effect of orchiectomy and estrogens of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900567-6

7 January 2021

The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900567-6

7 January 2021

Histological evaluation of benign prostatic hyperplasia treated by long-term administration of chlormadinone acetate (CMA).

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900567-6

7 January 2021

Treatment of benign prostatic hyperplasia with 5-alpha-reductase inhibitor: morphological changes in patients who fail to respond

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900567-6

7 January 2021

Quantitative evaluation of glandular and stromal compartments in hyperplastic dog prostates: effect of 5-alpha reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900567-6

7 January 2021

Morphological and hormonal changes in the ventral and dorsolateral prostatic lobes of rats treated with finasteride, a 5-alpha reductase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900567-6

7 January 2021

Light Microscopic Stereological Analysis of the Normal Human Prostate and of Benign Prostatic Hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900567-6

7 January 2021

Human benign prostatic hyperplasia: A stromal disease? New perspectives by quantitative morphology

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900567-6

7 January 2021

The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900567-6

7 January 2021

Morphometry of the prostate: I. Distribution of tissue components in hyperplastic glands

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900567-6

7 January 2021

Relationship between prostatic epithelial volume and serum prostate-specific antigen levels

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900567-6

7 January 2021

Serum PSA adjusted for volume of transition zone (PSAT) is more accurate than PSA adjusted for total gland volume (PSAD) in detecting adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900567-6

7 January 2021

Correlation between serum prostate specific antigen levels and the volume of the individual glandular zones of the human prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900567-6

7 January 2021

Serum prostate specific antigen levels after transurethral resection of prostate: a longitudinal characterization in men with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900567-6

7 January 2021

Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900567-6

7 January 2021

10.1016/S0090-4295(98)00567-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10096366%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

1 reference